Germany-headquartered Qiagen has announced that its NeuMoDx human immunodeficiency virus type 1 (HIV-1) assay has received approval for use in Thailand. Along with the previously approved hepatitis B virus (HBV) and hepatitis C virus (HCV) quantitative assays there is now a full complement of blood-borne virus (BBV) assays available in Thailand.

The NeuMoDx HIV-1 Quant Assay is designed for the quantitation and detection of human immunodeficiency virus type 1 (HIV-1) RNA in human plasma. It can be used as an aid in the clinical management of HIV-1 infected patients and monitoring the effects of anti-retroviral treatment, as measured by changes in plasma HIV-1 RNA levels, and as an aid in the diagnosis of HIV-1 infection, including acute or primary infection.

The NeuMoDx HBV Quant Assay is designed for the quantitation of hepatitis B virus (HBV) DNA in human plasma and serum specimens for HBV genotypes A through H of HBV-infected individuals. It is intended to be used as an aid for determining proper course of treatment for patients with HBV infection. The NeuMoDx HCV Quant Assay is designed for the quantitation of hepatitis C virus (HCV) RNA genotypes 1 through 6 in human plasma and serum specimens from HCV antibody positive individuals. It is intended to be used as an aid in the management of patients with HCV infections.

Along with blood-borne viruses, the NeuMoDx system has assays available for transplant-associated viruses, sexual and reproductive health as well as respiratory diseases.